Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
December 12 2017 - 11:55AM
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that
management will be hosting investor meetings at the Guggenheim
Securities 5th Annual Boston Healthcare Conference on Wednesday,
December 13, 2017 at The InterContinental Boston Hotel in Boston,
Massachusetts.
About Collegium Pharmaceutical,
Inc.
Collegium is a specialty pharmaceutical company focused on
developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and
other diseases. The DETERx technology platform is designed to
provide extended-release delivery, unique abuse-deterrent
properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx
technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA
for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which
alternative treatment options are inadequate.
Contact: Alex Dasallaadasalla@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024